Menu
Search
|

Menu

Close
X

Heat Biologics Inc HTBX.OQ (NASDAQ Stock Exchange Capital Market)

2.24 USD
-0.07 (-3.03%)
As of Jul 20
chart
Previous Close 2.31
Open 2.31
Volume 37,887
3m Avg Volume 244,069
Today’s High 2.31
Today’s Low 2.23
52 Week High 7.85
52 Week Low 1.09
Shares Outstanding (mil) 35.79
Market Capitalization (mil) 27.16
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
2
FY16
0
FY15
0
EPS (USD)
FY18
-0.749
FY17
-4.741
FY16
-8.932
FY15
-25.217
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
34.95
5.73
Price to Book (MRQ)
vs sector
2.67
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-114.78
14.61
Return on Equity (TTM)
vs sector
-175.18
16.34

EXECUTIVE LEADERSHIP

Jeffrey Wolf
Chairman of the Board, Chief Executive Officer, Since 2008
Salary: $404,583.00
Bonus: $202,500.00
Jeff Hutchins
Chief Operating Officer, Chief Scientific Officer, Since 2017
Salary: --
Bonus: --
Ann Rosar
Vice President - Finance, Controller, Corporate Secretary, Since 2016
Salary: $152,386.00
Bonus: $40,000.00
John Prendergast
Independent Lead Director, Since 2017
Salary: --
Bonus: --
John Monahan
Independent Director, Since 2009
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

801 Capitola Dr
DURHAM   NC   27713-4382

Phone: +1919.2407133

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

SPONSORED STORIES